WTW Stock Analysis: Willis Towers Watson | NASDAQ
Insurance Brokers | NASDAQ, USA | Market Cap: 31.761m USD | 12M Return: 6.5% | IE00BDB6Q211 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 178M
EPS Trend: 94.8%
Qual. Beats: 1
Rev. Trend: 82.2%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Willis Towers Watson (NASDAQ: WTW) is a London-based global advisory, broking, and solutions firm serving clients across two reportable segments: Health, Wealth & Career and Risk & Broking. The company provides strategy and design consulting, plan administration, actuarial support, and broking services for group benefits, pension, and retirement savings programs, as well as advice and software addressing total rewards and talent management.
In its Risk & Broking segment, WTW delivers insurance brokerage, risk advisory, and consulting across a wide range of specialty lines including property and casualty, aerospace, marine, natural resources, financial lines, and crisis management. The firm also offers technology, financial and regulatory reporting, capital modeling, M&A advisory, and business outsourcing services, reflecting the broader shift among large brokers toward integrated advisory platforms that combine consulting, brokerage commissions, and outsourced administration revenue.
Founded in 1828 and domiciled in the United Kingdom, the company was previously known as Willis Group Holdings and adopted its current name in January 2016. WTW is classified under the GICS Financials sector within the Multi-line Insurance sub-industry, and it trades on NASDAQ as a large-cap stock with origins in the London professional services market.
- Risk & Broking commissions rise on hard commercial insurance pricing
- Health and Benefits consulting grows amid employer benefit spending
- Share buybacks and dividends support capital return to shareholders
| Net Income: 1.56b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.55 > 1.0 |
| NWC/Revenue: 14.85% < 20% (prev 17.68%; Δ -2.83% < -1%) |
| CFO/TA 0.06 > 3% & CFO 1.92b > Net Income 1.56b |
| Net Debt (6.04b) to EBITDA (2.69b): 2.25 < 3 |
| Current Ratio: 1.10 > 1.5 & < 3 |
| Outstanding Shares: last quarter (94.0m) vs 12m ago -6.0% < -2% |
| Gross Margin: 38.41% > 18% (prev 43.56%; Δ -5.15% > 0.5%) |
| Asset Turnover: 34.22% > 50% (prev 34.44%; Δ -0.22% > 0%) |
| Interest Coverage Ratio: 8.07 > 6 (EBIT TTM 2.31b / Interest Expense TTM 286.0m) |
| A: 0.05 (Total Current Assets 16.7b - Total Current Liabilities 15.2b) / Total Assets 30.6b |
| B: -0.02 (Retained Earnings -699.0m / Total Assets 30.6b) |
| C: 0.08 (EBIT TTM 2.31b / Avg Total Assets 29.5b) |
| D: 0.34 (Book Value of Equity 7.69b / Total Liabilities 22.8b) |
| Altman-Z'' = 1.13 = BB |
| DSRI: 0.93 (Receivables 2.60b/2.71b, Revenue 10.1b/9.81b) |
| GMI: 1.13 (GM 43.56% / 38.41%) |
| AQI: 1.01 (AQ_t 0.41 / AQ_t-1 0.41) |
| SGI: 1.03 (Revenue 10.1b / 9.81b) |
| TATA: -0.01 (NI 1.56b - CFO 1.92b) / TA 30.6b) |
| Beneish M = -2.94 (Cap -4..+1) = A |
As of August 29, 2026, the stock is trading at USD 343.75 with a total of 311,422 shares traded. Over the past week, the price has changed by +0.51%, over one month by +8.73%, over three months by +36.90% and over the past year by +6.49%.
Current recommended Stop Loss: 333.60 (which is 3% or 1.3 ATR below the current price).
Willis Towers Watson has received a consensus analysts rating of 4.11. Therefore, it is recommended to buy WTW.
- StrongBuy: 8
- Buy: 5
- Hold: 4
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 380 | 10.5% |
P/E Trailing = 21.189
P/E Forward = 17.8571
P/S = 3.1441
P/B = 4.1297
P/EG = 1.08
Revenue TTM = 10.1b USD
EBIT TTM = 2.31b USD
EBITDA TTM = 2.69b USD
Long Term Debt = 5.78b USD (from longTermDebt, last quarter)
Short Term Debt = 866.0m USD (from shortTermDebt, last quarter)
Debt = 7.67b USD (from shortLongTermDebtTotal, last quarter) + Leases 571.0m
Net Debt = 6.04b USD (calculated: Debt 7.67b - CCE 1.63b)
Enterprise Value = 37.8b USD (31.8b + Debt 7.67b - CCE 1.63b)
Interest Coverage Ratio = 8.07 (Ebit TTM 2.31b / Interest Expense TTM 286.0m)
EV/FCF = 22.30x (Enterprise Value 37.8b / FCF TTM 1.70b)
FCF Yield = 4.48% (FCF TTM 1.70b / Enterprise Value 37.8b)
FCF Margin = 16.78% (FCF TTM 1.70b / Revenue TTM 10.1b)
Net Margin = 15.49% (Net Income TTM 1.56b / Revenue TTM 10.1b)
Gross Margin = 38.41% ((Revenue TTM 10.1b - Cost of Revenue TTM 6.22b) / Revenue TTM)
Gross Margin QoQ = 37.10% (prev 24.59%)
Tobins Q-Ratio = 1.24 (Enterprise Value 37.8b / Total Assets 30.6b)
Interest Expense / Debt = 3.73% (Interest Expense 286.0m / Debt 7.67b)
Taxrate = 20.21% (401.0m / 1.98b)
NOPAT = 1.84b (EBIT 2.31b * (1 - 20.21%))
Current Ratio = 1.10 (Total Current Assets 16.7b / Total Current Liabilities 15.2b)
Debt / Equity = 1.00 (Debt 7.67b / totalStockholderEquity, last quarter 7.69b)
Debt / EBITDA = 2.25 (Net Debt 6.04b / EBITDA 2.69b)
Debt / FCF = 3.57 (Net Debt 6.04b / FCF TTM 1.70b)
Total Stockholder Equity = 7.84b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.30% (Net Income 1.56b / Total Assets 30.6b)
RoE = 19.95% (Net Income TTM 1.56b / Total Stockholder Equity 7.84b)
RoCE = 16.94% (EBIT 2.31b / Capital Employed (Equity 7.84b + L.T.Debt 5.78b))
RoIC = 11.75% (NOPAT 1.84b / Invested Capital 15.7b)
WACC = 4.97% (E(31.8b)/V(39.4b) * Re(5.45%) + D(7.67b)/V(39.4b) * Rd(3.73%) * (1-Tc(0.20)))
Discount Rate = 5.45% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -96.61 | Cagr: -4.39%
[DCF] Terminal Value 77.97% ; FCFF base≈1.59b ; Y1≈1.82b ; Y5≈2.68b
[DCF] Fair Price = 368.7 (EV 40.3b - Net Debt 6.04b = Equity 34.2b / Shares 92.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 94.78 | EPS CAGR: 9.88% | SUE: 1.95 | # QB: 1
Revenue Correlation: 82.24 | Revenue CAGR: 2.05% | SUE: 1.51 | # QB: 1
EPS current Quarter (2026-09-30): EPS=3.61 | Chg30d=+1.10% | Revisions=+42% | Analysts=21
EPS current Year (2026-12-31): EPS=19.87 | Chg30d=+1.89% | Revisions=+83% | GrowthEPS=+16.3% | GrowthRev=+8.1%
EPS next Year (2027-12-31): EPS=22.89 | Chg30d=+3.27% | Revisions=+76% | GrowthEPS=+15.2% | GrowthRev=+5.1%
[Analyst] Revisions Ratio: +75% (up=44, down=5)